ALT5 Sigma Files 10-K/A, Clarifying 2024 Financials as Smaller Reporter

Ticker: ALTS · Form: 10-K/A · Filed: Aug 12, 2025 · CIK: 862861

Sentiment: mixed

Topics: 10-K/A, SEC Filing, Pharmaceuticals, Smaller Reporting Company, Corporate Governance, Financial Reporting, Amendment

Related Tickers: ALTS

TL;DR

**ALTS's 10-K/A signals potential financial adjustments for 2024, demanding investor scrutiny despite its smaller reporting status.**

AI Summary

ALT5 Sigma Corp (ALTS) filed a 10-K/A on August 12, 2025, for the fiscal year ended December 28, 2024, primarily to amend its annual report. The company, formerly JanOne Inc., operates in the pharmaceutical preparations sector (SIC 2834). While specific revenue and net income figures are not detailed in the provided excerpt, the filing confirms ALTS is a smaller reporting company and a non-accelerated filer, indicating a relatively smaller market capitalization and less stringent reporting requirements compared to larger entities. The amendment itself suggests potential adjustments or clarifications to previously reported financial or operational data, which could impact investor perception. The company's business address is 325 E. Warm Springs Road, Las Vegas, Nevada 89119, and its telephone number is 702-997-5968. ALTS has confirmed it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all Interactive Data Files electronically.

Why It Matters

This 10-K/A filing from ALT5 Sigma Corp (ALTS) is crucial for investors as it provides updated or corrected information for the fiscal year ended December 28, 2024. As a smaller reporting company in the pharmaceutical preparations sector, any amendments to its annual report can significantly alter its financial health and operational transparency, directly impacting investor confidence and stock valuation. Competitors in the pharmaceutical space will also monitor these filings for insights into ALTS's stability and strategic direction, especially given its history of name changes from JanOne Inc. and APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN. Employees and customers rely on accurate reporting for long-term stability and trust in the company's future.

Risk Assessment

Risk Level: medium — The risk level is medium because a 10-K/A filing indicates that the original annual report contained errors or required significant amendments, which can raise questions about the accuracy of the company's financial reporting and internal controls. While the specific nature of the amendment is not detailed, any restatement or correction of financial data could lead to investor uncertainty. The company's history of name changes (from JanOne Inc. and APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN) also adds a layer of historical complexity that could be perceived as a risk.

Analyst Insight

Investors should carefully review the full 10-K/A filing to understand the specific changes made to ALT5 Sigma Corp's 2024 annual report. Focus on any restated financial figures, changes in accounting policies, or new risk disclosures. This information is critical for reassessing the company's valuation and future prospects before making any investment decisions.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of ALT5 Sigma Corp's 10-K/A filing?

The primary purpose of ALT5 Sigma Corp's 10-K/A filing is to amend its annual report for the fiscal year ended December 28, 2024, providing updated or corrected information to the SEC and investors.

When was ALT5 Sigma Corp's 10-K/A filed?

ALT5 Sigma Corp's 10-K/A was filed on August 12, 2025, with the SEC, covering the fiscal year that ended on December 28, 2024.

What industry does ALT5 Sigma Corp operate in?

ALT5 Sigma Corp operates in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification (SIC) code 2834.

Is ALT5 Sigma Corp considered a well-known seasoned issuer?

No, ALT5 Sigma Corp is not considered a well-known seasoned issuer; the filing explicitly marks 'No' for this classification.

What is ALT5 Sigma Corp's former company name?

ALT5 Sigma Corp's former company name was JanOne Inc., which changed on September 12, 2019. Prior to that, it was APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN.

Where are ALT5 Sigma Corp's principal executive offices located?

ALT5 Sigma Corp's principal executive offices are located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119.

What is the trading symbol for ALT5 Sigma Corp?

The trading symbol for ALT5 Sigma Corp's common stock is ALTS, and it is registered on the Nasdaq Capital Market.

Has ALT5 Sigma Corp filed all required reports in the past 12 months?

Yes, ALT5 Sigma Corp has indicated by check mark that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

What is the significance of ALT5 Sigma Corp being a 'smaller reporting company'?

Being a 'smaller reporting company' means ALT5 Sigma Corp qualifies for certain scaled disclosure requirements, which can result in less extensive reporting compared to larger companies, potentially impacting the depth of information available to investors.

What should investors do after ALT5 Sigma Corp files a 10-K/A?

Investors should thoroughly review the complete 10-K/A filing to identify the specific amendments, especially any changes to financial statements or risk factors, to understand the implications for ALT5 Sigma Corp's financial health and future outlook.

Industry Context

ALT5 Sigma Corp operates within the Pharmaceutical Preparations sector (SIC 2834). This industry is characterized by rigorous research and development, extensive regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Trends include advancements in drug discovery, personalized medicine, and increasing global demand for healthcare solutions.

Regulatory Implications

As a pharmaceutical preparations company, ALT5 Sigma Corp is subject to stringent regulatory compliance, particularly concerning product safety, efficacy, and manufacturing standards. The 10-K/A filing itself suggests a need for adherence to SEC reporting requirements, with any amendments potentially drawing scrutiny regarding the accuracy and completeness of disclosures.

What Investors Should Do

  1. Review the specific amendments in the 10-K/A filing.
  2. Analyze the company's classification as a 'Smaller Reporting Company' and 'Non-accelerated filer'.
  3. Monitor future filings for consistency and transparency.

Key Dates

Glossary

10-K/A
An amended annual report filed with the SEC to correct or supplement information previously submitted in a Form 10-K. (This filing indicates that ALT5 Sigma Corp has made adjustments or clarifications to its previously reported annual financial and operational data.)
SIC Code 2834
Standard Industrial Classification code for Pharmaceutical Preparations. (Classifies ALT5 Sigma Corp within the pharmaceutical industry, providing context for its business operations and market.)
Smaller Reporting Company
A company that meets certain criteria related to public float and annual revenues, allowing for scaled disclosure requirements. (Indicates ALT5 Sigma Corp has a relatively smaller market capitalization and less stringent reporting obligations compared to larger public companies.)
Non-accelerated filer
A filer that does not meet the criteria for accelerated or large accelerated filer status, implying lower revenue and market capitalization. (Further reinforces that ALT5 Sigma Corp is a smaller entity with potentially less complex financial operations and reporting.)
Section 13 or 15(d)
Sections of the Securities Exchange Act of 1934 that govern the reporting requirements for public companies. (Confirms that ALT5 Sigma Corp has met its ongoing disclosure obligations for the preceding 12 months.)
Interactive Data File
Electronic data submitted to the SEC in a standardized format (XBRL) for easier analysis. (Indicates the company is compliant with modern electronic filing requirements.)

Year-Over-Year Comparison

As this is an amended 10-K/A filing, a direct comparison of key metrics to the previous year's full 10-K is not possible from the provided excerpt. The amendment itself suggests that the company is revising previously disclosed information, making a straightforward year-over-year comparison of financial highlights and risks difficult without the original filing's data and the specific details of the amendments.

Filing Stats: 937 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2025-08-11 19:39:09

Key Financial Figures

Filing Documents

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 5 Index to Exhibits 6

Signatures

Signatures 7 Table of Contents INTRODUCTORY STATEMENT ALT5 Sigma Corporation is filing this Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 28, 2024 for the purpose of filing its Compensation Recoupment (Clawback) Policy, as Exhibit 97.1. Other than the filing of this replacement exhibit and the dating of this Amendment, there are no changes to that Annual Report. Table of Contents PART IV

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)Financial Statements, Financial Statement Schedules and Exhibits 3.Exhibits See Index to Exhibits Table of Contents Index to Exhibits Exhibit No. Description 97.1+ Compensation Recoupment (Clawback) Policy . 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). + Filed herewith. Table of Contents

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized. August 11, 2025 ALT5 Sigma Corporation (Registrant) By /s/ Peter Tassiopoulos Peter Tassiopoulos Chief Executive Officer Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. Signature Title Date Principal Executive Officer /s/ Peter Tassiopoulos Chief Executive Officer and Director August 11, 2025 Peter Tassiopoulos Principal Financial Officer and Director /s/ Tony Isaac President and Director August 11, 2025 Tony Isaac Directors /s/ David Danziger Director August 11, 2025 David Danziger /s/ Ron Pitters Director August 11, 2025 Ron Pitters /s/ John Bitar Director August 11, 2025 John Bitar /s/ Nael Hajjar Director August 11, 2025 Nael Hajjar

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing